Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001

Selpercatinib is indicated for locally advanced/metastatic <i>RET</i>-activated solid tumors after progression or following prior systemic therapies. Until the recently published data from LIBRETTO-431 and LIBRETTO-531, there were limited effectiveness data comparing selpercatinib with o...

Full description

Bibliographic Details
Main Authors: Filippo De Braud, Barbara Deschler-Baier, John C. Morris, Francis Worden, Yimei Han, Urpo Kiiskinen, Min-Hua Jen, Scott S. Barker, Sylwia Szymczak, Adrienne M. Gilligan
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
LIBRETTO-001
post hoc
selpercatinib
standard therapy
retrospective
effectiveness outcomes
Online Access:https://www.mdpi.com/2072-6694/16/1/140

Internet

https://www.mdpi.com/2072-6694/16/1/140

Similar Items